Explore Genetic Factors Linked With Atypical Hemolytic Uremic Syndrome

Atypical hemolytic uremic syndrome is a rare condition involving abnormal activation of the complement system, which can damage blood vessels and affect kidney function. Genetic factors play an important role in many cases, although not everyone with a genetic change develops the condition. Variants affecting complement regulation may increase susceptibility to episodes, particularly when combined with triggers.

Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy in which uncontrolled activation of the complement system can contribute to injury of small blood vessels. Genetic changes affecting complement regulation are an important part of the disease mechanism, but aHUS is generally considered a complex condition because environmental or physiological triggers can also contribute to disease development.

Genetic Factors Associated With Atypical Hemolytic Uremic Syndrome

Several genes involved in regulating the complement system have been associated with increased susceptibility to aHUS. These genes normally help control complement activity and protect healthy cells and tissues from excessive immune-mediated damage.

Commonly studied genes include:

  • CFH: Provides instructions for complement factor H, an important regulator of the alternative complement pathway. Certain variants can reduce effective complement regulation.
  • CFI: Encodes complement factor I, which helps inactivate complement proteins. Changes in this gene may contribute to excessive complement activity.
  • CD46: Also known as membrane cofactor protein, CD46 helps regulate complement activation on cell surfaces. Some variants can impair this protective function.
  • C3: Produces a central complement component. Certain changes may increase complement activity and contribute to susceptibility.
  • CFB: Encodes complement factor B, which participates in alternative pathway activation. Some variants can promote increased complement activity.
  • DGKE: Changes in this gene have been associated with aHUS, particularly in younger patients, although its biological mechanism differs from many complement-related genes.

Not every person with a disease-associated genetic variant develops aHUS. This is partly because genetic susceptibility may require an additional trigger before clinical symptoms appear.

How Genetic Changes Can Influence Disease Risk

The relationship between genetics and aHUS is not always straightforward. Some individuals have identifiable genetic variants, while others have no currently recognized genetic cause. A person may also carry a genetic change without ever developing symptoms.

Potential factors that can contribute to disease activation include:

  • Infections that stimulate the immune system
  • Pregnancy and the postpartum period
  • Major surgery or physical stress
  • Certain medications or medical conditions
  • Other circumstances that increase complement system activity

Genetic testing can therefore be useful when a healthcare professional suspects aHUS, particularly in patients with unexplained thrombotic microangiopathy, recurrent episodes, or a relevant family history. Testing may examine several genes involved in complement regulation rather than focusing on a single gene.

Genetic findings can also have implications for family members. However, interpretation requires professional assessment because not every genetic variant is disease-causing, and the presence of a variant does not necessarily predict whether or when a person will develop aHUS.

In addition, genetic research continues to identify and clarify variants associated with complement-mediated diseases. A negative genetic test does not necessarily exclude aHUS because currently available testing cannot identify every possible genetic or acquired factor involved in the condition.

genetic factors can play an important role in susceptibility to atypical hemolytic uremic syndrome, particularly through changes affecting complement regulation. Genes such as CFH, CFI, CD46, C3, CFB, and DGKE have been associated with the condition. However, genetic predisposition is only one part of the disease process, and additional triggers may influence whether symptoms develop. Genetic testing should be interpreted alongside clinical findings and other laboratory information by qualified healthcare professionals. This information is educational only and is not intended to provide medical diagnosis, treatment, or individual medical advice.

Related Articles